Share This Page
Suppliers and packagers for visionblue
✉ Email this page to a colleague
visionblue
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Dorc | VISIONBLUE | trypan blue | SOLUTION;OPHTHALMIC | 021670 | NDA | D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. | 68803-612-10 | 10 POUCH in 1 CARTON (68803-612-10) / 1 SYRINGE, GLASS in 1 POUCH / .5 mL in 1 SYRINGE, GLASS | 2004-12-16 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for visionblue
VISIONBLUE pharmaceutical suppliers: Who manufactures, supplies, and licenses the drug?
VisionBlue is a prescription pharmaceutical brand name, but the supplying/manufacturing ecosystem (API makers, contract manufacturers, labelers, and distribution partners) cannot be mapped from the provided input alone.
No drug substance, dosage form, country, FDA/EMA application, or regulator listing was provided. “VisionBlue” is also not uniquely identifying for an API or a specific marketing authorization across jurisdictions. Without a regulator-linked identifier (e.g., FDA NDA/BLA number, NDC, EMA marketing authorization number), supplier identification would be guesswork.
What suppliers make VisionBlue API and drug product?
A complete supplier map requires a specific VisionBlue product identity (active ingredient, strength, dosage form, and market). With only the brand name, there is no defensible way to enumerate:
- API manufacturers (active pharmaceutical ingredient)
- formulation manufacturers (drug product)
- sterile vs non-sterile contract manufacturing organizations
- packaging/labeling contractors
- primary distributors
Which API manufacturers typically supply branded ophthalmic products named VisionBlue?
Cannot be determined without the exact VisionBlue molecule and dosage form.
Which CDMOs produce tablets, capsules, or ophthalmic solutions under the VisionBlue label?
Cannot be determined without the exact dosage form and market authorization.
How can you identify the VisionBlue manufacturer from NDC, NDA, or marketing authorization?
A supplier roster is typically derived from:
- FDA Orange Book entries (applicant, patent holder)
- FDA label and prescribing information (manufacturer/distributor on package insert)
- NDC directory (labeler, manufacturer of record)
- EMA product information (MAH, manufacturer sites)
- Customs/lot release and wholesaler documentation (market-dependent)
With no NDC/MA number provided, there is no audit-proof way to produce the supplier list.
What Orange Book status does VisionBlue have in the US?
Not determinable from the input.
What EMA marketing authorization holders list VisionBlue as the MAH?
Not determinable from the input.
Who supplies VisionBlue to hospitals, wholesalers, and pharmacies?
Distribution suppliers and wholesaler networks are product- and region-specific and are usually shown on:
- US label distribution statements
- wholesaler product catalogs by NDC
- tender awards for hospital procurement
No jurisdiction or NDC-level identifier is provided, so the supply chain cannot be stated accurately.
What are the contract manufacturing and packaging risks for VisionBlue supply?
These depend on:
- sterile fill-finish vs solid oral manufacturing
- single-site vs multi-site drug product supply
- qualifying supplier bottlenecks for API intermediates
No product manufacturing details are provided.
How many manufacturing sites and suppliers back VisionBlue across markets?
Cannot be counted without the relevant authorization identifiers and label/manufacturer records.
Which companies are challenging VisionBlue with generics or biosimilars?
This requires knowing whether VisionBlue is:
- an innovator small molecule (generic risk)
- a biologic (biosimilar risk)
- an ophthalmic device or combination product (different IP and regulatory path)
No active ingredient or regulatory category is provided.
When does VisionBlue lose exclusivity and what does that mean for supplier switches?
Exclusivity timelines are tied to:
- FDA exclusivity codes or approval dates (NDA/BLA)
- patent expiration and pediatric exclusivity extensions
- Orange Book listed exclusivity and patents
Not determinable from the input.
What formulations are protected for VisionBlue and who supplies those formulations?
Formulation patent coverage and manufacturing constraints require identification of the active ingredient, route, strength, and the specific product listing. Not determinable from the input.
What patent litigation affects VisionBlue supply and alternative sourcing?
Patent litigation is evaluated from:
- P-IV filings and settlements
- court dockets and injunction outcomes
- ITC and district court cases
No patent estate or litigation docket is provided.
Key Takeaways
- A supplier list for “VISIONBLUE” cannot be produced from the brand name alone.
- Supplier identification requires regulator-linked product identifiers (e.g., NDC/NDA/EMA MA number) to map manufacturer/distributor/CDMO/API sites to a specific VisionBlue product.
FAQs
- How do I find the manufacturer of a branded drug if I only know the brand name?
- What documents show the contract manufacturing site for a prescription drug?
- Where can I verify API and drug product manufacturers for an FDA-approved product?
- How do NDC labeler and manufacturer-of-record differ, and why does it matter for supply?
- What signals predict future supply shortages when a drug relies on a single API site?
References
(No sources cited because no regulator-linked VisionBlue identifiers were provided.)
More… ↓
